For patients with metastatic radioctive iodine refractory papillary thyroid carcinoma that is BRAF V600E mutant and rapidly progressive, would you consider dabrafenib/trametinib combo instead of lenvantinib or sorafenib first line?

This is an ongoing debate among endocrine and head and neck oncologists; we have phase III data of lenvantinib which is pretty strong, although with tolerance issues when used at full approved doses (24 mg/day, SELECT trial). On the other hand, there is only phase 2 data for BRAF positive DTC using ...